Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The Why & What of the ACR’s Clinical Practice Guidelines

Ruth Jessen Hickman, MD  |  Issue: February 2018  |  February 18, 2018

Clinicians must realize the inherent limitations of any clinical practice guidelines, including those produced by the ACR. In the absence of a perfect evidence base, guidelines can still provide helpful, evidence-based guidance for those making clinical decisions.

ACR guideline writers make clear that clinical guidelines are not prescriptive & should be used by clinicians & patients only as a guide for discussion.

How Are the ACR Guidelines Generated?

The ACR strives to produce guidelines that provide the best possible evidence-based guidance to clinicians, while being transparent about any limitations in the evidence base for particular recommendations. The ACR guideline development process complies with standards from the National Academy of Medicine (formerly the Institute of Medicine) and the Council for Medical Subspecialty Societies. ACR guidelines are developed using a rigorous, multi-step process involving several coordinated groups of experts. Prior to the process, all members of the guideline group undergo orientation to prepare them for their specific roles.

The first step is assembling a group of experts who will work to develop the guideline, starting by identifying the project’s scope. Tuhina Neogi, MD, PhD, FRCPC, is a practicing rheumatologist and professor of medicine and epidemiology at the Boston University School of Medicine. She participated in developing the 2012 gout treatment guidelines, and she is one of the core team leaders for the osteoarthritis guideline, currently in process.

Dr. Neogi

Dr. Neogi

Dr. Neogi explains, “Usually the people who are leading the effort [help the ACR] identify appropriate candidates to populate the broader team that will be working on the treatment guidelines.”

Liron Caplan, MD, PhD, is an associate professor of medicine and rheumatology at the University of Colorado School of Medicine in Aurora, Colo. He was the literature review leader for the ACR’s axial spondyloarthritis (SpA) guideline and currently serves as the ACR Guideline Subcommittee chair. Dr. Caplan says, “In the case of the ACR, they require that more than half of the guideline development team have no conflicts of interest with regard to industry support in the topic area of the guideline.” The team includes members with content expertise and expertise in methodology and guideline development.

The next stage is identifying the most important clinical questions and outcomes the guideline needs to address. An expert panel works with the broader guideline development team to provide guidance and advice on the most clinically appropriate questions to include. “There are many more questions than are feasible to be addressed in a given treatment guideline,” says Dr. Neogi. “To have the treatment guidelines be relevant and also doable and digestible, there has to be some curation involved.” Before proceeding further, members of the larger community have an opportunity to shape these questions via a public comment period.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 4 5 6 7 8 9 10 | Single Page
Share: 

Filed under:Practice Support Tagged with:Clinical Practice GuidelinesThe American College of Rheumatology

Related Articles
    Dr. Caplan turned 106 on Nov. 21 and remains physically and mentally active.

    Paul S. Caplan, MD: A Physician’s Journey

    March 8, 2020

    Editor’s note: It is with much sadness that we learned this morning that Paul Caplan, MD, passed away yesterday, March 7, 2020. “He was a remarkable person who continued to celebrate life up to the end,” says Terence W. Starz, MD, University of Pittsburgh School of Medicine. “He had a great caring, wisdom, and commitment…

    Alisusha; Trueffelpix / shutterstock.com

    3 New Vasculitis Guidelines Discussed

    May 13, 2021

    The ACR, in concert with the Vasculitis Foundation, released three new vasculitis guidelines online first in July, with a fourth slated for publication by the end of the year. These are the first ever to be produced and endorsed by the ACR and the Vasculitis Foundation. Although most of the recommendations are conditional, due to…

    Vasculitis Guidelines in Focus, Part 6: Giant Cell Arteritis

    September 27, 2022

    In 2021, the ACR—in concert with the Vasculitis Foundation (VF)—released four new vasculitis guidelines, one each on: 1) anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, 2) giant cell arteritis (GCA) and Takayasu arteritis, 3) polyarteritis nodosa and 4) Kawasaki disease. The guideline development process is complex. For the vasculitis guidelines, this process kicked off in June…

    Updated Perioperative Guideline Released: Recommendations Balance Risks of Infection & Disease Flare

    September 13, 2022

    The 2017 recommendations are updated to reflect changes in medical literature, as well as to include newly approved drugs.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences